Altimmune said on Thursday that it plans to test its lead experimental obesity drug, pemvidutide, to potentially treat ...

Novo Nordisk on Monday revealed weaker-than-expected data from a second late-stage trial of its obesity drug candidate ...

Roche has acquired rights to an obesity therapy by Denmark's Zealand Pharma in a collaboration deal worth up to $5.3 billion, ...

Semaglutide and tirzepatide confer greater improvements in life expectancy than naltrexone/bupropion and ...

The administration is reviewing a Centers for Medicare and Medicaid Services rule that would expand coverage to Medicare and Medicaid recipients ...

Obesity is a major global health issue, increasing the risk of heart disease, diabetes, and high blood pressure. Despite many ...

The Maryland-based biopharma joins Eli Lilly and Novo Nordisk in trialing a GLP-1 agonist for alcohol- and liver-related ...

Roche partnered with Zealand Pharma to license an experimental weight loss drug for $1.65 billion upfront, expanding its ...

A new study found that fair prices for medications like Wegovy and Zepbound would be hundreds less per month than they are ...

Obesity and pharmacology experts are warning about hidden safety risks and efficacy issues for many types of medications in ...

The deal provides Viking Therapeutics with a secured dedicated annual supply of both injectable and oral versions of its ...

Novo Nordisk and Eli Lilly currently control 99% of the market, but their dominance may weaken as new entrants introduce ...